Seeking Alpha

Matthew Rossi's  Instablog

Matthew Rossi
Send Message
MarketDNA is a product of SJL Capital LLC. SJL Capital LLC is a Registered Investment Advisory firm that was formed in March, 2005. MarketDNA is a proprietary quantitative analysis program which was created in 1996 and then tested and fine-tuned over the last 14 years. The unique methodology of... More
My company:
MarketDNA
My blog:
MarketDNA
My book:
MarketDNA
  • PLX Continues its climb via dual listing 0 comments
    Sep 7, 2010 8:43 AM | about stocks: PLX

    MarketDNA Update Alert

    September 7, 2010
    Buy: Equity - PLX, Protalix Biotherapeutics Inc., - $7.22
    Buy: Derivatives - PLX101016C5, -PLX101016C7.5, October 5 & October 7.5 Calls
    Equity Target: $10.00
    Potential Event: Unknown inefficiency in dissemination of information.
    Risks: Medium.

    Investors,

    Last week on August 30th, we updated you on the news that PLX would be dual listed on the Tel Aviv stock exchange along with their current US listing.  Yesterday, PLX started to trade in Tel Aviv and the gain was impressive with the spillover hitting us here today. 

    Pre-market has PLX trading at $8.20 to $8.30 which would give us a 14.25% gain from our initial price of $7.22 in 2 weeks.  We strongly recommend a hedging strategy here to lock in your gains at this point.

    We will hold our alert open on PLX and look for additional data points in the near term.

    As always, we will continue to monitor PLX and bring you timely actionable trading alerts on all our equities based on our proprietary investment program.

    Good luck investing.

     

    MarketDNA is a unique and very accurate proprietary research channel.MarketDNA uncovers trading which is occurring based on inefficiencies in dissemination of information, typically within fourteen days prior to an event occurring on the equity. MarketDNA provides our clients with actionable opportunity based intelligence and a suite of ala carte custom research solutions, all with exceptional track records and value.

     

    IMPORTANT DISCLOSURES 
    The distribution of this information has been made to a select group of which every effort has been made to disseminate the information to everyone at the same time. The information contained herein, including any expression of opinion, has been obtained from, or is based upon, sources believed by us to be reliable, but is not guaranteed as to accuracy or completeness.  This is not intended to be an offer to buy or sell or a solicitation of the securities, if any, referred to herein. Our firm and/or its officers and employees from time to time have a position in one or more of the securities mentioned herein. SJL Capital LLC does not trade on recommended equities based on
    MarketDNA research for 15 minutes after release of the distributed email alert.  The information and opinions in this report were prepared by MarketDNA and obtained from sources believed to be reliable. MarketDNA in no way guarantees the accuracy or completeness of such information. This report has been prepared for informational purposes only and was issued by MarketDNA for distribution to our market professional, institutional investor & individual customers. Nothing in this report constitutes investment, legal, accounting or tax advice or a representation that any investment or strategy is suitable or appropriate to your individual circumstances, nor does this constitute a personal recommendation to you. Opinions expressed are subject to change without notice and past performance is no guarantee of future result.


    Matthew Rossi
    Founder, Managing Partner & Chief Research Officer
    MarketDNAInvestment Newsletter - A product of SJL Capital LLC

    eqix

     

    www.MarketDNA.com


    MarketDNA 

    MarketDNA Research Alert

    August 25, 2010
    Buy: Equity - PLX, Protalix Biotherapeutics Inc., - $7.22
    Buy: Derivatives - PLX101016C5, -PLX101016C7.5, October 5 & October 7.5 Calls
    Equity Target: $10.00
    Potential Event: Unknown inefficiency in dissemination of information.
    Risks: Medium.

    Investors,

    We are seeing multiple indications of a potential upward movement for PLX, Protalix Biotherapeutics Inc., from our proprietary investment program and believe PLX will move up to $10 within the next two months. The option chart below shows the increase in call options over the last several weeks which we believe is based on an impending move up for PLX.

    Why PLX:
    • Increase in Option Volume
    • Increase in Open Interest
    • Increase in Implied Volatility
    • Trailing P/E (ttm, intraday) N/A
    • Forward P/E (fye Dec 31, 2011) N/A
    • Price/Sales (ttm) 210.84
    • Price/Book (mrq) N/A
    • Enterprise Value/Revenue (ttm) N/A
    • Enterprise Value/EBITDA (ttm) N/A
    PLX Options    PLX Stock

    Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on the ProCellEx protein expression system (ProCellEx). Using the ProCellEx system, the Company is developing a pipeline of biosimilar or generic versions of recombinant therapeutic proteins based on the plant cell-based expression technology, which focuses pharmaceutical markets and that rely upon known biological mechanisms of action. The ProCellEx protein expression system consists of a set of technologies and capabilities for the development of recombinant proteins, including advanced genetic engineering technology and plant cell-based protein expression methods. The ProCellEx protein expression system is built on bioreactors made of polyethylene and optimized for the development of complex proteins in plant cell cultures.

    Taliglucerase Alfa

    Taliglucerase alfa is a plant cell expressed recombinant glucocerebrosidase enzyme (GCD) for the treatment of Gaucher disease. In September 2009, the Company successfully completed the phase III pivotal clinical trial of taliglucerase alfa. In June 2006, the Company completed a phase I clinical trial of taliglucerase alfa. The phase I clinical trial was a single-center, non-randomized, open label, dose ranging study designed to evaluate the safety and pharmacokinetics of taliglucerase alfa in healthy subjects. The trial was conducted on healthy subjects over a four-week period in which subjects received three single escalating doses of taliglucerase alfa administered as intravenous infusions.

    PRX-102

    The Company is developing the alpha Galactosidase enzyme, titled as PRX-102, which is a therapeutic enzyme for the treatment of Fabry disease, a rare genetic lysosomal storage disorder in humans, the symptoms of which involve the accumulation of lipids in the cells of the kidneys, heart and other organs. It is conducting the animal evaluation testing phase of the development of PRX-102, which tests are based on a mouse model for Fabry disease.

    Acetylcholinesterase

    In August 2007, the Company entered into an agreement with the Yissum Research and Development Company and the Boyce Thompson Institute, Inc. pursuant to which it is developing a plant cell-based acetylcholinesterase (AChE) and its molecular variants for the use in therapeutic and prophylactic indications, as well as in a biodefense program and an organophosphate-based pesticide treatment program.

    In January 2008, the Company expanded the scope of the acetylcholinesterase program with Yissum after it received the proof of concept results in an animal study conducted as part of the program. In the animal study, the plant cell expressed form of the acetylcholinesterase protein demonstrated protection from organophosphate-based pesticide treatment program.

    pr-antiTNF

    In September 2009, the Company announced the preliminary preclinical data regarding an antiTNF (tumor, necrosis factor) protein. It has designed the antiNF as pr-antiNF. pr-antiNF is a candidate for the treatment of certain autoimmune diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing, spondylitis, psoriatic arthritis and plaque psoriasis. pr-antiTNF is a plant cell-expressed recombinant fusion protein made from the soluble form of the human TNF receptor (TNFR), fused to the Fc component of a human antibody domain. pr-antiTNF has an identical amino acid sequence to Enbrel and the in vitro and preclinical animal studies have demonstrated that pr-antiTNF exhibits similar activity to Enbrel. Specifically, pr-antiTNF binds TNF thereby inhibiting it from binding to cellular surface TNF receptors and protects L929 cells from TNF-induced apoptosis in a dose-dependent manner.

    The Company competes with Amicus Therapeutics, Inc., Crucell N.V., Shire and GlycoFi, Inc., Biolex, Inc., Chlorogen, Inc., Greenovation Biotech GmbH, Symbiosys, Novartis AG/Sandoz Pharmaceuticals, BioGeneriX AG, Stada Arzneimittel AG, BioPartners GmbH and Teva.

    Currently trading at about $7.22, we believe, based on our proprietary program, an upward movement to $10.00 within the next two months is forthcoming. PLX trades on average 300,000 shares per day, and PLX has traded up from $6 back in May.

     

    We recommend buying the equity straight out at $7.25 or less. If you like derivatives, we recommend the October 5 Calls.  If you want to take additional risk/reward the October 7.5 Calls are also recommended.

    ADDITIONAL METRICS:


    RELATED COMPANIES:

    Ticker

    Company name

    Exchange

    Price

    Change

    Chg %

    Earnings per share

    P/E ratio

    Mkt Cap

    PLX

    Protalix BioTherapeuti...

    AMEX

    7.22

    +0.26

    3.63%

    -0.49

     

    589.63M

    TEVA

    Teva Pharmaceutical In...

    NASDAQ

    49.99

    +0.02

    0.04%

    2.79

    17.89

    46.74B

    PFE

    Pfizer Inc.

    NYSE

    15.77

    -0.05

    -0.32%

    1.26

    12.48

    127.20B

    GENZ

    Genzyme Corporation

    NASDAQ

    66.71

    -0.68

    -1.01%

    -0.30

     

    17.00B

    FOLD

    Amicus Therapeutics, Inc.

    NASDAQ

    3.05

    -0.04

    -1.18%

    -0.29

     

    84.40M

    SHPGY

    Shire Plc. (ADR)

    NASDAQ

    64.26

    -1.03

    -1.58%

    2.98

    21.57

    12.04B

    ALTUQ

    Altus Pharmaceuticals ...

    PINK

    0.0190

    0.0000

    0.00%

    -2.33

     

    591,490.00

    PSTI

    Pluristem Therapeutics...

    NASDAQ

    1.04

    +0.01

    0.97%

    -0.46

     

    21.75M

    LIFE

    Life Technologies Corp.

    NASDAQ

    43.82

    -0.19

    -0.43%

    1.55

    28.33

    8.03B

             
             
             
                  
                    

     

    FINANCIALS:

    In Millions of USD(except for per share items)

    3 months ending 2009-09-30

    3 months ending 2009-06-30

    Revenue

    1.14

    1.14

    Other Revenue, Total

    -

    -

    Total Revenue

    1.14

    1.14

    Cost of Revenue, Total

    -

    -

    Gross Profit

    1.14

    1.14

    Selling/General/Admin. Expenses, Total

    1.26

    1.62

    Research & Development

    10.51

    8.91

    Depreciation/Amortization

    -

    -

    Interest Expense(Income) - Net Operating

    -

    -

    Unusual Expense (Income)

    -

    -

    Other Operating Expenses, Total

    -0.48

    -1.27

    Total Operating Expense

    11.29

    9.26

    Operating Income

    -10.15

    -8.12

    Interest Income(Expense), Net Non-Operating

    0.11

    0.17

    Gain (Loss) on Sale of Assets

    -

    -

    Other, Net

    -

    -

    Income Before Tax

    -10.04

    -7.96

    Income After Tax

    -10.04

    -7.96

    Minority Interest

    -

    -

    Equity In Affiliates

    -

    -

    Net Income Before Extra. Items

    -10.04

    -7.96

    Accounting Change

    -

    -

    Discontinued Operations

    -

    -

    Extraordinary Item

    -

    -

    Net Income

    -10.04

    -7.96

                                                          


    Good luck investing.

     

    MarketDNA is a unique and very accurate proprietary research channel.MarketDNA uncovers trading which is occurring based on inefficiencies in dissemination of information, typically within fourteen days prior to an event occurring on the equity. MarketDNA provides our clients with actionable opportunity based intelligence and a suite of ala carte custom research solutions, all with exceptional track records and value.

     

    IMPORTANT DISCLOSURES 
    The distribution of this information has been made to a select group of which every effort has been made to disseminate the information to everyone at the same time. The information contained herein, including any expression of opinion, has been obtained from, or is based upon, sources believed by us to be reliable, but is not guaranteed as to accuracy or completeness.  This is not intended to be an offer to buy or sell or a solicitation of the securities, if any, referred to herein. Our firm and/or its officers and employees from time to time have a position in one or more of the securities mentioned herein. SJL Capital LLC does not trade on recommended equities based on
    MarketDNA research for 15 minutes after release of the distributed email alert.  The information and opinions in this report were prepared by MarketDNA and obtained from sources believed to be reliable. MarketDNA in no way guarantees the accuracy or completeness of such information. This report has been prepared for informational purposes only and was issued by MarketDNA for distribution to our market professional, institutional investor & individual customers. Nothing in this report constitutes investment, legal, accounting or tax advice or a representation that any investment or strategy is suitable or appropriate to your individual circumstances, nor does this constitute a personal recommendation to you. Opinions expressed are subject to change without notice and past performance is no guarantee of future result.


     

    Matthew Rossi
    Founder, Managing Partner & Chief Research Officer
    MarketDNAInvestment Newsletter - A product of SJL Capital LLC

    eqix

     

    www.MarketDNA.com





    Disclosure: We currently hold a position in PLX
    Stocks: PLX
Back To Matthew Rossi's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.